Alglucosidase Alfa Temporary Access Program (ATAP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The objective of this expanded access study is to provide patients with Pompe disease in the United States (US), access to alglucosidase alfa produced from a scaled up manufacturing process for a limited time until production at this scale is approved for commercial use by the Food and Drug Administration.
Condition or disease
Glycogen Storage Disease Type II (GSD-II)Pompe Disease (Late-Onset)Acid Maltase DeficiencyDiseaseGlycogenosis 2
Biological: alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
The patient or patient's legal guardian must provide signed, informed consent prior to performing any study-related procedures.
The patient must reside in the US.
The patient must have a confirmed diagnosis of Pompe disease defined as documented acid alpha-glucosidase (GAA) enzyme deficiency from any tissue source and/or GAA gene mutations.
The patient must have/had documented clinical signs and symptoms of Pompe disease.
The patient must have/had prior treatment with alglucosidase alfa produced at commercial scale OR be naive to enzyme replacement therapy (ERT) for the treatment of Pompe disease and meet at least 1 of the following criteria: require a wheelchair OR require some respiratory assistance for any number of hours (including night time) through non-invasive ventilation.
The patient must be capable of complying with the required program schedule of assessments.
Females who are pregnant or lactating
The patient has a clinical condition unrelated to Pompe disease that would interfere with program assessments.
The patient is currently enrolled in any clinical studies.